I-Myeloid Leukemia: Unyango oluPhumelelayo olutsha

A BAMBA isiKhululo sasimahla 2 | eTurboNews | eTN

I-Ascentage Pharma, inkampani yehlabathi jikelele ye-biopharmaceutical ebandakanyeka ekuphuhliseni iinoveli zonyango lwe-cancer, i-hepatitis B engapheliyo (CHB), kunye nezifo ezinxulumene neminyaka yobudala, kunye ne-Innovent Biologics, Inc. ("Innovent"), inkampani yehlabathi ye-biopharmaceutical ephuhlisayo, eyenza. kwaye ithengisa amayeza akumgangatho ophezulu kunyango lwe-oncology, metabolic, autoimmune kunye nezinye izifo ezikhulu, ngokudibeneyo babhengeze ukuba inoveli yomgqatswa weyeza i-olverembatinib yaseGuangzhou HealthQuest Pharma Co., Ltd., Inc., i-subsidiary ephethwe ngokupheleleyo ye-Ascentage Pharma, ine ivunyiwe yi-China National Medical Products Administration (NMPA) kunyango lwezigulane zabantu abadala abane-tyrosine kinase inhibitor (TKI)-resistant phase chronic chronic myeloid leukemia (CML-CP) okanye i-CML-phase ekhawulezayo (CML-AP) egcina i-T315I ukuguqulwa kwenguqu njengoko kuqinisekiswa luvavanyo oluqinisekisiweyo lokuxilonga (uphawu olungavunywanga e-US).

Iphuhliswe yi-Ascentage Pharma ngenkxaso evela kwiNkqubo yeSizwe yokuFumana kweZiyobisi eziNtsha kunye neNkqubo yokuVelisa, i-olverembatinib lichiza elinokuba ligqwesileyo kwiklasi eliya kuthengiswa ngokubambisana kwimakethi yaseTshayina yi-Innovent kunye ne-Ascentage Pharma, ukuze kuxhamle izigulana ezininzi kunye nezabo. iintsapho. Njengoko isizukulwana sokuqala sesithathu saseTshayina i-BCL-ABL TKI iphuhliselwe unyango lwe-TKI-resistant CML, olu lwamkelo luzalisa isithuba sonyango esibalulekileyo kwi-T315I-mutant CML, kwaye iphawula isiganeko esibalulekileyo esibonisa ukuba i-Ascentage Pharma ingene ngempumelelo kwinqanaba lorhwebo.

Le mvume ye-olverembatinib isekelwe kwiziphumo ezivela kwizifundo ezimbini ezibalulekileyo zeSigaba sesi-II - uphononongo lwe-HQP1351CC201 kunye nophononongo lwe-HQP1351CC202. Ezi ziphumo zibonise ukuba i-olverembatinib iyasebenza kwaye inyamezeleke kakuhle kwizigulane ezine-CML-CP kunye ne-CML-AP, kwaye amathuba kunye nobunzulu bempendulo yeklinikhi kulindeleke ukuba kwandiswe kunye nexesha elide lonyango.

I-CML yi-hematological malignancy yeeseli ezimhlophe zegazi. Ukuqaliswa kwe-BCR-ABL TKIs iphucule kakhulu ulawulo lweklinikhi ye-CML. Nangona kunjalo, ukuxhathisa okufunyenweyo kwii-TKIs kuhlala kungumngeni omkhulu kunyango lwe-CML. Ukuguqulwa kwe-BCR-ABL tyrosine kinase kubonisa indlela ephambili yokuxhathisa iziyobisi; I-T315I, lolona tshintsho luxhaphakileyo lokunganyangeki ngamachiza, lwenzeka malunga ne-25% yezigulane ezine-CML enganyangekiyo ngamachiza. Izigulana ezine-T315I-mutant CML ziyaxhathisa kwisizukulwana sokuqala kunye nesesibini kwisizukulwana se-BCR-ABL inhibitors, kungoko zibonakalisa imfuno yonyango engxamisekileyo yonyango olusebenzayo.

Malunga nombhali

I-avatar kaLinda Hohnholz, umhleli we-eTN

U-Linda Hohnholz, umhleli we-eTN

U-Linda Hohnholz ubhale kwaye wahlela amanqaku ukusukela oko waqalisa ukusebenza. Usebenzise olu thando lwangaphakathi kwiindawo ezinje ngeHawaii Pacific University, iYunivesithi yaseChaminade, iZiko lokuFumanisa abantwana laseHawaii, kwaye ngoku iTravelNewsGroup.

Bhlisa
Yaziswe ngawo
guest
0 izimvo
Inline feedbacks
Jonga zonke izimvo
0
Ndingazithanda iingcinga zakho, nceda uphawule.x
Yabelana ku...